Morgan Stanley lowered the firm’s price target on NeoGenomics (NEO) to $8 from $10 and keeps an Equal Weight rating on the shares after Q2 revenue came in below expectations due to continued pharma softness and guidance was lowered to reflect biopharma headwinds and the delayed commercial launch of PanTracer LBx.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics downgraded to Neutral from Buy at BTIG
- NeoGenomics Reports Revenue Growth Amid Rising Losses
- NeoGenomics: Potential Upside Amidst Challenges and Low Valuation
- NeoGenomics: Buy Rating Affirmed Amid Stable Growth and Strategic Focus Despite Near-Term Challenges
- William Blair downgrades NeoGenomics, says rebuilding credibility will take time